Your browser doesn't support javascript.
loading
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
Rimassa, Lorenza; Kelley, Robin Kate; Meyer, Tim; Ryoo, Baek-Yeol; Merle, Philippe; Park, Joong-Won; Blanc, Jean-Frederic; Lim, Ho Yeong; Tran, Albert; Chan, Yi-Wah; McAdam, Paul; Wang, Evelyn; Cheng, Ann-Lii; El-Khoueiry, Anthony B; Abou-Alfa, Ghassan K.
Afiliação
  • Rimassa L; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.
  • Kelley RK; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy.
  • Meyer T; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
  • Ryoo BY; Royal Free Hospital and UCL Cancer Institute, London, United Kingdom.
  • Merle P; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Park JW; Groupement Hospitalier Lyon Nord, Lyon, France.
  • Blanc JF; National Cancer Center, Goyang, Republic of Korea.
  • Lim HY; Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France.
  • Tran A; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Chan YW; Université Côte d'Azur, Nice, France.
  • McAdam P; CHU de Nice, Digestive Center, Nice, France.
  • Wang E; INSERM, U1065, C3M, Team 8, Nice, France.
  • Cheng AL; Fios Genomics Ltd, Edinburgh, United Kingdom.
  • El-Khoueiry AB; Fios Genomics Ltd, Edinburgh, United Kingdom.
  • Abou-Alfa GK; Exelixis, Inc., Alameda, California, USA.
Liver Cancer ; 11(1): 38-47, 2022 Jan.
Article em En | MEDLINE | ID: mdl-35222506

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article